Literature DB >> 7548469

Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia.

R Freedman1, M Hall, L E Adler, S Leonard.   

Abstract

This study tests the hypothesis that nicotinic cholinergic receptors, including those sensitive to the antagonist alpha-bungarotoxin, are decreased in the hippocampus of schizophrenics. The hypothesis is derived from the finding that alpha-bungarotoxin causes a defect in the inhibitory gating of auditory-evoked potentials in laboratory animals that resembles a defect in auditory sensory gating observed in schizophrenics. Nicotine transiently normalizes this psychophysiological deficit in schizophrenic patients. Postmortem brain tissue was obtained from eight schizophrenic and eight age-matched nonschizophrenic subjects. Sections of the hippocampus were labeled with [125I alpha-bungarotoxin and imagined by autoradiography. Binding of the nicotinic agonist [3H]-cytisine was determined in tissue homogenates. alpha-Bungarotoxin labeled a population of putative interneurons in the hippocampus, primarily in the dentate gyrus and the CA3 region of Ammon's horn. This labeling was significantly decreased in the tissue from the schizophrenic patients, with seven or eight patients below the range of the nonschizophrenic subjects. There was also a significant decrease in the binding of cytisine. The results were not related to generalized hippocampal cell loss, drug exposure at time of death, or smoking history. This initial study suggests that schizophrenic patients have fewer nicotinic receptors in the hippocampus, a condition which may lead to failure of cholinergic activation of inhibitory interneurons, manifest clinically as decreased gating of response to sensory stimulation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7548469     DOI: 10.1016/0006-3223(94)00252-X

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  206 in total

1.  The regulation of hippocampal nicotinic acetylcholine receptors (nAChRs) after a protracted treatment with selective or nonselective nAChR agonists.

Authors:  J Auta; P Longone; A Guidotti; E Costa
Journal:  J Mol Neurosci       Date:  1999 Aug-Oct       Impact factor: 3.444

Review 2.  The genetics of sensory gating deficits in schizophrenia.

Authors:  Robert Freedman; Ann Olincy; Randall G Ross; Merilyne C Waldo; Karen E Stevens; Lawrence E Adler; Sherry Leonard
Journal:  Curr Psychiatry Rep       Date:  2003-06       Impact factor: 5.285

Review 3.  Cognitive effects of nicotine: genetic moderators.

Authors:  Aryeh I Herman; Mehmet Sofuoglu
Journal:  Addict Biol       Date:  2010-04-29       Impact factor: 4.280

4.  Nicotinic acetylcholine receptor expression on B-lymphoblasts of healthy versus schizophrenic subjects stratified for smoking: [3H]-nicotine binding is decreased in schizophrenia and correlates with negative symptoms.

Authors:  Christian Luckhaus; Uwe Henning; Stefano Ferrea; Francesco Musso; Arian Mobascher; Georg Winterer
Journal:  J Neural Transm (Vienna)       Date:  2011-12-11       Impact factor: 3.575

Review 5.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

6.  Transcriptional repression of the α7 nicotinic acetylcholine receptor subunit gene (CHRNA7) by activating protein-2α (AP-2α).

Authors:  Jessica Finlay-Schultz; Andrew Canastar; Margaret Short; Mohamed El Gazzar; Christina Coughlan; Sherry Leonard
Journal:  J Biol Chem       Date:  2011-10-06       Impact factor: 5.157

7.  Promoter IV-BDNF deficiency disturbs cholinergic gene expression of CHRNA5, CHRM2, and CHRM5: effects of drug and environmental treatments.

Authors:  Kazuko Sakata; Abigail E Overacre
Journal:  J Neurochem       Date:  2017-08-16       Impact factor: 5.372

Review 8.  Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

Authors:  Ann Olincy; Karen E Stevens
Journal:  Biochem Pharmacol       Date:  2007-07-17       Impact factor: 5.858

Review 9.  Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.

Authors:  Edward D Levin; Amir H Rezvani
Journal:  Biochem Pharmacol       Date:  2007-07-20       Impact factor: 5.858

10.  P50 inhibitory sensory gating in schizophrenia: analysis of recent studies.

Authors:  Robert Freedman; Amanda M Olsen-Dufour; Ann Olincy
Journal:  Schizophr Res       Date:  2020-02-13       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.